Next Article in Journal
Label-Free Sensors Based on Graphene Field-Effect Transistors for the Detection of Human Chorionic Gonadotropin Cancer Risk Biomarker
Previous Article in Journal / Special Issue
Non-Invasive Renal Perfusion Imaging Using Arterial Spin Labeling MRI: Challenges and Opportunities
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessTechnical Note
Diagnostics 2018, 8(1), 3; https://doi.org/10.3390/diagnostics8010003

Renal Cell Carcinoma Perfusion before and after Radiofrequency Ablation Measured with Dynamic Contrast Enhanced MRI: A Pilot Study

1
Department of Diagnostic and Interventional Radiology, Institute of Oncology, Leeds Teaching Hospitals Trust, St. James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK
2
Division of Medical Physics, University of Leeds, Leeds LS2 9JT, UK
3
Department of Medical Physics, St. James’s University Teaching Hospital, Beckett Street, Leeds LS9 7TF, UK
4
School of Computing, University of Leeds, Leeds LS2 9JT, UK
5
Professor of Statistical Methodology in Clinical Trials, Clinical Trials Research Unit (CTRU), University of Leeds, Clinical Trials Research House 71-75 Clarendon Road, Leeds LS2 9PH, UK
6
Professor of Cancer Medicine, Leeds Institute of Molecular Medicine, St. James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK
*
Author to whom correspondence should be addressed.
Received: 20 November 2017 / Revised: 28 December 2017 / Accepted: 2 January 2018 / Published: 8 January 2018
(This article belongs to the Special Issue Functional and Molecular Imaging of Kidney and Urogenital Disease)
View Full-Text   |   Download PDF [2758 KB, uploaded 8 January 2018]   |  

Abstract

Aim: To investigate if the early treatment effects of radiofrequency ablation (RFA) on renal cell carcinoma (RCC) can be detected with dynamic contrast enhanced (DCE)-MRI and to correlate RCC perfusion with RFA treatment time. Materials and methods: 20 patients undergoing RFA of their 21 RCCs were evaluated with DCE-MRI before and at one month after RFA treatment. Perfusion was estimated using the maximum slope technique at two independent sittings. Total RCC blood flow was correlated with total RFA treatment time, tumour location, size and histology. Results: DCE-MRI examinations were successfully evaluated for 21 RCCs (size from 1.3 to 4 cm). Perfusion of the RCCs decreased significantly (p < 0.0001) from a mean of 203 (±80) mL/min/100 mL before RFA to 8.1 (±3.1) mL/min/100 mL after RFA with low intra-observer variability (r ≥ 0.99, p < 0.0001). There was an excellent correlation (r = 0.95) between time to complete ablation and pre-treatment total RCC blood flow. Tumours with an exophytic location exhibit the lowest mean RFA treatment time. Conclusion: DCE-MRI can detect early treatment effects by measuring RCC perfusion before and after RFA. Perfusion significantly decreases in the zone of ablation, suggesting that it may be useful for the assessment of treatment efficacy. Pre-RFA RCC blood flow may be used to predict RFA treatment time. View Full-Text
Keywords: radiofrequency ablation; quantitative measurement; perfusion; MRI; renal cell carcinoma radiofrequency ablation; quantitative measurement; perfusion; MRI; renal cell carcinoma
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Wah, T.M.; Sourbron, S.; Wilson, D.J.; Magee, D.; Gregory, W.M.; Selby, P.J.; Buckley, D.L. Renal Cell Carcinoma Perfusion before and after Radiofrequency Ablation Measured with Dynamic Contrast Enhanced MRI: A Pilot Study. Diagnostics 2018, 8, 3.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top